Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

T3 Pharmaceuticals AG. (11/23/16). "Press Release: T3 Pharma Closes First Financing Round to Advance Research and Preclinical Development of Breakthrough Bacteria-based Cancer Therapies". Basel.

Organisations Organisation T3 Pharmaceuticals AG
  Organisation 2 PRIVATE INVESTORS
  Group OTHER
Products Product bacterial cancer drug
  Product 2 venture capital
Index term Index term T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors
Person Person Ittig, Simon Josef (T3 Pharmaceuticals 201909 CEO)
     


T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation of preclinical development.

The financing round complements the successful efforts raising significant non-dilutive capital from the Swiss Commission for Technology and Innovation and various research foundations.

T3 Pharma is a spin-off from the Biozentrum of the University of Basel. The Company focuses on novel therapies for cancer patients. T3 Pharma has been engineering live bacteria to specifically infect solid tumors and fighting them with a proprietary protein delivery technology developed at the University of Basel.

“Our strong investor base and the support by the University of Basel provide perfect conditions for the development of our breakthrough technology in cancer therapies”, said Dr. Simon Ittig, CEO and co-founder of T3 Pharma. “This first financing round allows us to advance initial lead candidates into preclinical development.”

“It belongs to the mission of a modern University to help translating basic research into tangible benefits for patients and society,” explained Prof. Dr. Erich Nigg, Director of the Biozentrum. “We hope that T3 Pharma can exploit their innovative platform to bring novel treatments to cancer patients.”


* * *


For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 267 20 74
Email: s.ittig@t3pharma.com


About T3 Pharma

The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors. For further information, please visit www.t3pharma.com

   
Record changed: 2019-10-07

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for T3 Pharmaceuticals AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75




» top